Logo image of TCRR

TCR2 THERAPEUTICS INC (TCRR) Stock Analyst Ratings

USA - NASDAQ:TCRR - US87808K1060 - Common Stock

1.48 USD
-0.09 (-5.73%)
Last: 5/31/2023, 8:00:02 PM
1.53 USD
+0.05 (+3.38%)
After Hours: 5/31/2023, 8:00:02 PM
Buy % Consensus

73

ChartMill assigns a Buy % Consensus number of 73% to TCRR. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 5.86. This target is 295.87% above the current price.
TCRR was analyzed by 12 analysts. The buy percentage consensus is at 73. So analysts seem to be have mildly positive about TCRR.
In the previous month the buy percentage consensus was at a similar level.
TCRR was analyzed by 12 analysts, which is quite many. So the average rating should be quite meaningful.

Related screens

TCRR Historical Analyst RatingsTCRR Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -50 -45 -40 -35 -30 -25 -20 -15 -10 -5 0 5 10 15

Price Target & Forecast

Price Low Median Mean High 1.481.742.045.8621.00 - 17.38% 37.84% 295.87% 1,318.92%

Related screens

TCRR Current Analyst RatingTCRR Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 1 2 3 4 5
Up and Down Grades
Date Firm Action Rating
2023-03-24 Mizuho Downgrade Buy -> Neutral
2023-03-23 EF Hutton Reiterate Hold
2023-03-09 Jefferies Downgrade Buy -> Underperform
2023-03-08 Truist Securities Downgrade Buy -> Hold
2023-03-07 HC Wainwright & Co. Downgrade Buy -> Neutral
2023-01-06 Piper Sandler Maintains Overweight
2023-01-05 EF Hutton Initiate Hold
2022-11-21 HC Wainwright & Co. Maintains Buy
2022-11-08 SVB Leerink Maintains Market Perform
2022-05-19 HC Wainwright & Co. Maintains Buy
2022-01-19 Goldman Sachs Downgrade Buy -> Neutral
2022-01-13 HC Wainwright & Co. Maintains Buy
2021-11-10 SVB Leerink Maintains Market Perform
2021-10-21 SVB Leerink Downgrade Outperform -> Market Perform
2021-09-20 Truist Securities Maintains Buy
2021-09-20 HC Wainwright & Co. Maintains Buy
2021-08-06 SVB Leerink Maintains Outperform
2021-06-24 Goldman Sachs Initiate Buy
2021-03-11 SVB Leerink Maintains Outperform

TCR2 THERAPEUTICS INC / TCRR FAQ

What is the price target for TCRR stock?

12 analysts have analysed TCRR and the average price target is 5.86 USD. This implies a price increase of 295.87% is expected in the next year compared to the current price of 1.48.


How do analysts rate TCR2 THERAPEUTICS INC (TCRR)?

The consensus rating for TCR2 THERAPEUTICS INC (TCRR) is 73.3333 / 100 . This indicates that analysts generally have a positive outlook on the stock.